Brian Chang's questions to Coherus Oncology (CHRS) leadership • Q2 2025
Question
Asked about the importance and timing of securing a partner for the CHS-114 (CCR8) program and about the company's confidence in achieving its revenue goals for Loktorzi.
Answer
The company is funded for CHS-114 through key data readouts in H1 2026 but expects partners to help offset future development costs. Partnering timing is influenced by competitor data expected in the next 6-12 months. They are confident in the Loktorzi revenue goal ($150M-$200M peak), citing strong uptake in academic centers following NCCN guideline updates, and are now focused on educating the community setting.